NASDAQ:SLGL - Sol Gel Technologies Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $6.91 -0.03 (-0.43 %) (As of 11/13/2018 03:42 PM ET)Previous Close$6.94Today's Range$6.91 - $7.0152-Week Range$5.98 - $16.48Volume358 shsAverage Volume9,369 shsMarket Capitalization$132.65 millionP/E Ratio-1.42Dividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea. It is also involved in the development of generic dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo; and Douglas Pharmaceuticals for the development and commercialization of a generic product candidate. The company was founded in 1997 and is headquartered in Ness Ziona, Israel. Receive SLGL News and Ratings via Email Sign-up to receive the latest news and ratings for SLGL and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SLGL Previous Symbol CUSIPN/A Webwww.sol-gel.com Phone972-8931-3433 Debt Debt-to-Equity RatioN/A Current Ratio20.81 Quick Ratio20.81 Price-To-Earnings Trailing P/E Ratio-1.42 Forward P/E Ratio-3.51 P/E GrowthN/A Sales & Book Value Annual Sales$170,000.00 Price / Sales769.04 Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees49 Outstanding Shares18,920,000Market Cap$132.65 million OptionableNot Optionable Sol Gel Technologies (NASDAQ:SLGL) Frequently Asked Questions What is Sol Gel Technologies' stock symbol? Sol Gel Technologies trades on the NASDAQ under the ticker symbol "SLGL." How were Sol Gel Technologies' earnings last quarter? Sol Gel Technologies Ltd (NASDAQ:SLGL) posted its earnings results on Wednesday, August, 8th. The company reported ($0.36) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.48) by $0.12. The company earned $0.05 million during the quarter, compared to the consensus estimate of $0.05 million. View Sol Gel Technologies' Earnings History. When is Sol Gel Technologies' next earnings date? Sol Gel Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, November 14th 2018. View Earnings Estimates for Sol Gel Technologies. What price target have analysts set for SLGL? 4 Wall Street analysts have issued 12-month price targets for Sol Gel Technologies' shares. Their predictions range from $17.00 to $21.00. On average, they expect Sol Gel Technologies' share price to reach $19.00 in the next year. This suggests a possible upside of 175.0% from the stock's current price. View Analyst Price Targets for Sol Gel Technologies. What is the consensus analysts' recommendation for Sol Gel Technologies? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sol Gel Technologies in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sol Gel Technologies. What are Wall Street analysts saying about Sol Gel Technologies stock? Here are some recent quotes from research analysts about Sol Gel Technologies stock: 1. HC Wainwright analysts commented, "We have valued Sol-Gel based on a discounted cash flow (DCF)-based analysis. This yields a value of $102M for TWIN, assuming a 50% probability of success, and a $323M valuation for VERED, assuming a 60% probability of success." (9/26/2018) 2. According to Zacks Investment Research, "Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel. " (7/18/2018) Has Sol Gel Technologies been receiving favorable news coverage? News coverage about SLGL stock has been trending somewhat negative this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sol Gel Technologies earned a news impact score of -1.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the company's share price in the next several days. Who are some of Sol Gel Technologies' key competitors? Some companies that are related to Sol Gel Technologies include Collegium Pharmaceutical (COLL), Akebia Therapeutics (AKBA), ChemoCentryx (CCXI), Prothena (PRTA), Xeris Pharmaceuticals (XERS), Aurinia Pharmaceuticals (AUPH), Dova Pharmaceuticals (DOVA), Rigel Pharmaceuticals (RIGL), Kezar Life Sciences (KZR), Eidos Therapeutics (EIDX), Odonate Therapeutics (ODT), TG Therapeutics (TGTX), Theratechnologies (THERF), Progenics Pharmaceuticals (PGNX) and Corium International (CORI). Who are Sol Gel Technologies' key executives? Sol Gel Technologies' management team includes the folowing people: Dr. Alon Seri-Levy, Co-Founder, CEO & Director (Age 57)Prof. David Avnir, Co-FounderMr. Gilad Mamlok, Chief Financial Officer (Age 50)Mr. Itzik Yosef, VP of Operations (Age 42)Ms. Karine Neimann, VP of Projects & Planning and Chief Chemist (Age 47) When did Sol Gel Technologies IPO? (SLGL) raised $60 million in an initial public offering on Thursday, February 1st 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. Jefferies and BMO Capital Markets served as the underwriters for the IPO and JMP Securities and Raymond James were co-managers. How do I buy shares of Sol Gel Technologies? Shares of SLGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Sol Gel Technologies' stock price today? One share of SLGL stock can currently be purchased for approximately $6.91. How big of a company is Sol Gel Technologies? Sol Gel Technologies has a market capitalization of $132.65 million and generates $170,000.00 in revenue each year. The company earns $-31,560,000.00 in net income (profit) each year or ($5.02) on an earnings per share basis. Sol Gel Technologies employs 49 workers across the globe. What is Sol Gel Technologies' official website? The official website for Sol Gel Technologies is http://www.sol-gel.com. How can I contact Sol Gel Technologies? Sol Gel Technologies' mailing address is 7 GOLDA MEIR ST.WEIZMANN SCIENCE PARK, NESS ZIONA L3, 7403650. The company can be reached via phone at 972-8931-3433. MarketBeat Community Rating for Sol Gel Technologies (NASDAQ SLGL)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 60 (Vote Outperform)Underperform Votes: 70 (Vote Underperform)Total Votes: 130MarketBeat's community ratings are surveys of what our community members think about Sol Gel Technologies and other stocks. Vote "Outperform" if you believe SLGL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLGL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/13/2018 by MarketBeat.com StaffFeatured Article: What is dollar cost averaging (DCA)?